• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NanoVibronix touts trigeminal neuralgia PainShield study data

NanoVibronix touts trigeminal neuralgia PainShield study data

July 25, 2018 By Fink Densford

NanoVibronix

NanoVibronix (NSDQ:NAOV) yesterday released results from a study exploring the use of its PainShield device in treating patients with trigeminal neuralgia, touting improved pain relief and quality of life.

The PainShield is a device designed to treat pain in nerves, muscles and joints through the delivery of localized ultrasound, the Elmsford, N.Y.-based company said.

In the 59-patient double blinded, crossover trial, investigators examined the use of the device in treating individuals with unilateral trigeminal neuralgia using assessments on the Visual Analog Scale pain score as well as breakthrough medications per week. Breakthrough medications in the trial were used for chronic pain related to pre-existing trigeminal neuralgia conditions.

Results indicated that patients treated with the PainShield saw a 55.2% improvement from their baseline VAS scores after treatment, compared to only a 2.3% increase for patients in the control group. Patients treated with the PainShield also saw a 46.4% reduction in breakthrough pain medication, versus only 1.5% in the control group.

“We are very pleased to report the final results of our PainShield study for patients with Trigeminal Neuralgia. We saw a dramatic improvement in both pain scores and the use of pain medications such as opioids. We look forward to having these results published in a leading medical journal and aggressively marketing the device to physicians in order to help the millions of patients worldwide suffering from this painful and debilitating condition. Given the current opioid crisis, the fact we can help reduce dependence on medications, will also help save lives. This was a very challenging patient population and we look forward to conducting similar studies, where we believe we can replicate our success for other painful conditions,” CEO Brian Murphy said in a press release.

In December, NanoVibronix said that it inked a deal with the U.K.’s IMS Ultrasound to make it the exclusive U.K. distributor of its UroShield device, designed to prevent catheter-acquired urinary tract infections.

Filed Under: Clinical Trials, Pain Management, Ultrasound Tagged With: nanovibronix

More recent news

  • Neuronetics names Steven Pfanstiel chief financial officer
  • Medtronic to distribute Future Medical’s peripheral guidewires
  • AtriCure completes enrollment in stroke prevention trial
  • GT Medical raises $53M to support brain tumor treatment
  • Imperative Care, Proximie partner to develop surgical robot to treat stroke

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy